Shares of Avantor, Inc. (NYSE:AVTR – Get Free Report) have received a consensus rating of “Hold” from the fifteen brokerages that are covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $15.50.
Several analysts have issued reports on AVTR shares. Evercore ISI dropped their target price on Avantor from $18.00 to $16.00 and set an “outperform” rating for the company in a report on Monday, August 4th. Stifel Nicolaus set a $12.00 price objective on shares of Avantor and gave the company a “hold” rating in a report on Monday, August 4th. Wells Fargo & Company reduced their target price on shares of Avantor from $19.00 to $16.00 and set an “overweight” rating on the stock in a research note on Monday, August 4th. Raymond James Financial set a $14.00 target price on shares of Avantor and gave the company an “outperform” rating in a report on Monday, August 4th. Finally, Royal Bank Of Canada dropped their price target on shares of Avantor from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Monday, August 4th.
Get Our Latest Analysis on Avantor
Avantor Stock Up 9.7%
Avantor (NYSE:AVTR – Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Avantor had a net margin of 10.31% and a return on equity of 11.39%. The company had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion. During the same quarter last year, the company earned $0.25 earnings per share. Avantor’s revenue for the quarter was down 1.1% on a year-over-year basis. As a group, analysts forecast that Avantor will post 1.06 earnings per share for the current fiscal year.
Insider Transactions at Avantor
In other Avantor news, CAO Steven W. Eck sold 3,476 shares of Avantor stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $11.39, for a total value of $39,591.64. Following the sale, the chief accounting officer owned 55,068 shares in the company, valued at $627,224.52. The trade was a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is currently owned by company insiders.
Institutional Trading of Avantor
Several institutional investors and hedge funds have recently bought and sold shares of AVTR. Rise Advisors LLC acquired a new position in Avantor in the first quarter valued at about $25,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Avantor by 288.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,701 shares of the company’s stock worth $28,000 after acquiring an additional 1,263 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Avantor by 119.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after acquiring an additional 1,189 shares during the last quarter. Strategic Wealth Investment Group LLC purchased a new position in shares of Avantor during the 2nd quarter worth approximately $32,000. Finally, Wealthquest Corp acquired a new stake in Avantor in the 1st quarter valued at approximately $34,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Recommended Stories
- Five stocks we like better than Avantor
- 3 Warren Buffett Stocks to Buy Now
- Datavault AI: The New AI Contender Backed by Big Funding
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- Want to Profit on the Downtrend? Downtrends, Explained.
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.